In 2010 Clinuvel commenced its vitiligo program to evaluate the use of its first-in-class drug SCENESSE® (afamelanotide 16mg) as a repigmentation therapy in adults with generalised vitiligo.

The first of these studies, CUV102, has completed, with treatment results released in December 2012. Follow up results from this study were published in 2013 and were peer-review published in JAMA Dermatology in 2014. A further trial, CUV103, commenced in Singapore in 2014. Preliminary results from the CUV103 study were released in December 2015, along with an update on the Company's planned North American Development program for vitiligo.

Clinuvel has established this webpage to serve as a portal for all information relevant to this study and vitiligo more broadly.

Clinuvel Stock Ticker

Quick Links